{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:57:58Z","timestamp":1767135478631,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd009191.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000}}],"reference-count":65,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009191.pub4","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T16:52:11Z","timestamp":1640105531000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease"],"prefix":"10.1002","volume":"2021","author":[{"given":"Teguh Haryo","family":"Sasongko","sequence":"additional","affiliation":[{"name":"Perdana University RCSI School of Medicine; Perdana University (PU); Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth","family":"Nagalla","sequence":"additional","affiliation":[{"name":"Benign Hematology; Miami Cancer Institute; Miami Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD009191.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(98)00056-4","article-title":"A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia","volume":"104","author":"Foucan","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009191.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0002-9343(99)80341-6","article-title":"Enalapril reduces the albuminuria in patients with sickle cell disease","volume":"98","author":"Aoki","year":"1995","journal-title":"American Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD009191.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJM199204023261402","article-title":"Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme","volume":"326","author":"Falk","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009191.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.20296","article-title":"Enalapril and hydroxyurea therapy for children with sickle nephropathy","volume":"45","author":"Fitzhugh","year":"2005","journal-title":"Pediatric Blood and Cancer"},{"issue":"3","key":"10.1002\/14651858.CD009191.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MPH.0b013e3180335081","article-title":"Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease","volume":"29","author":"McKie","year":"2007","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0006|cit6","unstructured":"Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children (MADREPIEC) clinicaltrials.gov\/ct2\/show\/record\/NCT01096121"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0007|cit7","unstructured":"Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy clinicaltrials.gov\/ct2\/show\/NCT01891292"},{"issue":"3","key":"10.1002\/14651858.CD009191.pub4-BIB0008|cit8","first-page":"300","article-title":"Incidence of haemoglobinopathies detected through neonatal screening in the United Arab Emirates","volume":"11","author":"Al Hosani","year":"2005","journal-title":"La Revue de Sant\u00e9 de la M\u00e9diterran\u00e9e Orientale"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0009|cit9","unstructured":"High Blood Pressure (Hypertension) www.kidneyfund.org\/kidney-health\/are-you-at-risk\/high-blood-pressure.html"},{"issue":"6","key":"10.1002\/14651858.CD009191.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"Journal of Clinical Investigation"},{"issue":"4","key":"10.1002\/14651858.CD009191.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1096-8652(200004)63:4<205::AID-AJH8>3.0.CO;2-8","article-title":"Renal Abnormalities in Sickle Cell Disease","volume":"63","author":"Ataga","year":"2000","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD009191.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"257\u201363","DOI":"10.1111\/j.1600-0609.2010.01471.x","article-title":"Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1","volume":"85","author":"Ataga","year":"2010","journal-title":"European Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD009191.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00467-010-1536-8","article-title":"Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease","volume":"25","author":"Becton","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD009191.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.21570","article-title":"The number of people with sickle-cell disease in the United States: national and state estimates","volume":"85","author":"Brousseau","year":"2009","journal-title":"American Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD009191.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/ndt\/gfl839","article-title":"Angiotensin blockade as a sole treatment for proteinuric kidney disease in children","volume":"22","author":"Chandar","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD009191.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00062752-200203000-00005","article-title":"Sickle cell disease in Africa","volume":"9","author":"Diallo","year":"2002","journal-title":"Current Opinion in Hematology"},{"issue":"19","key":"10.1002\/14651858.CD009191.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomised trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009191.pub4-BIB0018|cit18","first-page":"23","article-title":"Sickle cell disease in the post genomic era: a monogenic disease with a polygenic phenotype","volume":"2009","author":"Driss","year":"2009","journal-title":"Genomic Insights"},{"issue":"1","key":"10.1002\/14651858.CD009191.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD009191.pub4-BIB0020|cit20","first-page":"185","article-title":"Renal function studies in pediatrics. 1. Renal hemodynamics in children with sickle cell anemia","volume":"83","author":"Etteldorf","year":"1952","journal-title":"American Medical Association. American Journal of Diseases of Children"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0021|cit21","first-page":"133","article-title":"Sickle cell nephropathy","volume":"23","author":"Falk","year":"1994","journal-title":"Advances in Nephrology from the Necker Hospital"},{"issue":"4","key":"10.1002\/14651858.CD009191.pub4-BIB0022|cit22","first-page":"279","article-title":"Mortality of children with sickle cell disease: a population study","volume":"86","author":"Fernandes","year":"2010","journal-title":"Jornal de Pediatria"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"937\u201340","DOI":"10.1002\/pbc.23338","article-title":"Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease","volume":"58","author":"Forrest","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1002\/14651858.CD009191.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/ki.1996.109","article-title":"Early detection and the course of glomerular injury in patients with sickle cell anemia","volume":"49","author":"Guasch","year":"1996","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD009191.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/ki.1997.116","article-title":"Sickle cell anaemia causes a distinct pattern of glomerular dysfunction","volume":"51","author":"Guasch","year":"1997","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD009191.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1681\/ASN.V1051014","article-title":"Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans","volume":"10","author":"Guasch","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7414","key":"10.1002\/14651858.CD009191.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0028|cit28","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"9722","key":"10.1002\/14651858.CD009191.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(09)62004-3","article-title":"Early recognition and prevention of chronic kidney disease","volume":"375","author":"James","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009191.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2006.07.001","article-title":"Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes","volume":"21","author":"Kato","year":"2007","journal-title":"Blood Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009191.pub4-BIB0031|cit31","first-page":"15","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease","volume":"68","author":"Kolesnyk","year":"2010","journal-title":"Netherlands Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD009191.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543780903247463","article-title":"Investigational drugs in sickle cell anemia","volume":"18","author":"Kotiah","year":"2009","journal-title":"Expert Opinion of Investigational Drugs"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0033|cit33","unstructured":"Lerma EV Sickle cell nephropathy: treatment & medication emedicine.medscape.com\/article\/247004-treatment"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Lottenberg R Hassell KL An evidence-based approach to the treatment of adults with sickle cell disease Hematology American Society of Hematology Education Program 2005 58 65","DOI":"10.1182\/asheducation-2005.1.58"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0035|cit35","unstructured":"End-stage kidney disease www.nlm.nih.gov\/medlineplus\/ency\/article\/000500.htm"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0036|cit36","volume-title":"NHS Sickle Cell and Thalassemia Screening Programme","author":"National Screening Committee","year":"2006"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0037|cit37","unstructured":"National Institute of Health National Heart Lung and Blood Institute Division of Blood Diseases and Resources The Management of Sickle Cell Disease 4th edition NIH Publication"},{"issue":"2","key":"10.1002\/14651858.CD009191.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0016-5085(89)90081-4","article-title":"Early indicators of prognosis in fulminant hepatic failure","volume":"97","author":"O'Grady","year":"1989","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD009191.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1073\/pnas.0409876102","article-title":"Impaired vasodilation by red blood cells in sickle cell disease","volume":"102","author":"Pawloski","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1002\/14651858.CD009191.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2000.00806.x","article-title":"Renal abnormalities in sickle cell disease","volume":"57","author":"Pham","year":"2000","journal-title":"Kidney International"},{"issue":"23","key":"10.1002\/14651858.CD009191.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009191.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"Powars","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"10.1002\/14651858.CD009191.pub4-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0044|cit44","volume-title":"Lecture Notes; Clinical Pharmacology and Therapeutics","author":"Reid","year":"2006"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0045|cit45","unstructured":"ACE inhibitors General Monograph www.rxmed.com\/b.main\/b2.pharmaceutical\/b2.1.monographs\/CPS-%20Monographs\/CPS-%20(General%20Monographs-%20A)\/ACE%20INHIBITORS.html"},{"issue":"1","key":"10.1002\/14651858.CD009191.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.V101187","article-title":"Sickle cell nephropathy","volume":"10","author":"Saborio","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD009191.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ncpneph1008","article-title":"Sickle cell disease and the kidney","volume":"5","author":"Scheinman","year":"2009","journal-title":"Nature Clinical Practice Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD009191.pub4-BIB0048|cit48","first-page":"364","article-title":"Sickle cell disease; a general overview","volume":"62","author":"Schnog","year":"2004","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0049|cit49","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0050|cit50","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0051|cit51","volume-title":"Sickle Cell Disease","author":"Serjeant","year":"1992"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0052|cit52","unstructured":"Essentials of the Diagnosis of Heart Failure www.aafp.org\/afp\/20000301\/1319.html"},{"issue":"3","key":"10.1002\/14651858.CD009191.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2141.2011.08853.x","article-title":"Sickle cell nephropathy \u2013 a practical approach","volume":"155","author":"Sharpe","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"13","key":"10.1002\/14651858.CD009191.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199904013401307","article-title":"Management of sickle cell disease","volume":"340","author":"Steinberg","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009191.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tips.2006.02.007","article-title":"Pathophysiologically based drug treatment of sickle cell disease","volume":"27","author":"Steinberg","year":"2006","journal-title":"TRENDS in Pharmacological Sciences"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0056|cit56","unstructured":"Steiner C Miller J HCUP Statistical Brief #21. Sickle Cell Disease Patients in U.S. Hospitals, 2004 www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb21.pdf"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0057|cit57","volume-title":"Medical Pharmacology and Therapeutics","author":"Waller","year":"2005"},{"issue":"1","key":"10.1002\/14651858.CD009191.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2009.06.060","article-title":"Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"156","author":"Ware","year":"2010","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD009191.pub4-BIB0059|cit59","unstructured":"Comprehensive Metabolic Panel www.webmd.com\/a-to-z-guides\/comprehensive-metabolic-panel-topic-overview"},{"issue":"6","key":"10.1002\/14651858.CD009191.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1046\/j.1523-1755.2002.00363.x","article-title":"The initiation and progression of sickle cell nephropathy","volume":"61","author":"Wesson","year":"2002","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD009191.pub4-BIB0061|cit61","first-page":"749","article-title":"Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease","volume":"136","author":"Wigfall","year":"2000","journal-title":"Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD009191.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2215\/CJN.05631207","article-title":"A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease","volume":"3","author":"Xie","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD009191.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD009191.pub4-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009191.pub2","article-title":"Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease","author":"Sasongko","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD009191.pub4-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009191.pub3","article-title":"Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease","author":"Sasongko","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T22:17:29Z","timestamp":1733350649000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009191.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009191.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}